The National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of Russia has developed a preventive drug against monkeypox (mpox). Research work on creating a vaccine has essentially been completed, the director of the institution, Alexander Ginzburg.
The next stage is preclinical trials, which could last six to seven months. “We are waiting for the ‘clinic’ to be financed, since this is a lot of money, we cannot do it ourselves,” the scientist added. He did not name the exact amount needed to conduct clinical trials.
Ginzburg argues that including the MMR vaccine in the national immunization schedule is illogical. It would be more effective to administer the vaccine based on epidemiological indications. It is necessary to vaccinate the patient, his entourage, as well as the second and third circle of contacts.
